Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMP766
- Development stage
- Discontinued
- Lead developer
- Conifer Point
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LMP766 is an orally bioavailable small molecule inhibitor of tumor necrosis factor-alpha (TNF-alpha) synthesis. Developed by Locus Pharmaceuticals using their proprietary computational fragment-based drug design platform, LMP766 was designed to treat inflammatory conditions such as Crohn's disease and rheumatoid arthritis. Unlike monoclonal antibody biologics that neutralize circulating TNF-alpha protein, LMP766 acts intracellularly to inhibit the production of TNF-alpha at the cellular level. Clinical development reached Phase 2 for the treatment of Crohn's disease; however, the program was ultimately terminated, and the developer, Locus Pharmaceuticals, ceased operations around 2010.
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on LMP766.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMP766.